Company record · updated October 7, 2026
Oruka Therapeutics Inc: 3 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs April 30, 2024 to April 30, 2024.
3observations
3source filings
3verified rows
2024-04-30most recent as-of date
Source rails for this company: N-PORT fund mark (3).
Reported by 3 filers: Fidelity Advisor Biotechnology Fund, Fidelity Small Cap Growth Fund, Fidelity Small Cap Growth K6 Fund.
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2024-04-30 | price per share | 5.9402 USD | Fidelity Small Cap Growth K6 Fund | VERIFIED | valUSD 1354823.0 / balance 228077.0 [unspecified] | 000175272424151265 |
| 2024-04-30 | price per share | 5.9402 USD | Fidelity Small Cap Growth Fund | VERIFIED | valUSD 3645179.97 / balance 613646.0 [unspecified] | 000175272424151254 |
| 2024-04-30 | price per share | 5.9402 USD | Fidelity Advisor Biotechnology Fund | VERIFIED | valUSD 4000000.0 / balance 673378.0 [unspecified] | 000175272424151078 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price.